The clinically relevant cut-off for tryptase is higher (15 ng/mL) in order to include healthy individuals with HαT and all other controls, whereas in most patients with systemic mastocytosis (SM), tryptase levels are higher (>15 ng/mL). Here, TMPRSS11D is linked to systemic mastocytosis.